🚨 Breaking #ASCO22 News: Breakthrough findings published in NEJM by MSK experts Andrea Cercek & Luis Diaz show 100% complete response rate in all patients who received #immunotherapy treatment for mismatch repair deficient locally advanced #RectalCancer. bit.ly/3NnXSib

“I believe this is the first time this has happened in the history of cancer,” Dr. Diaz said. Still, the trial will need to be replicated in other patients. nyti.ms/38QRMHX

Well deserved ovation to Dr. Andrea Cercek and the GI Onc team at Memorial Sloan Kettering Cancer Center . Yes, you’re reading well: 100% cCCR in pts w/ MSI-H / dMMR LA Rectal Cancer w/ IO. This means possibly no need for CT, RT or Surgery! This is a game changer for our patients!

Alan Burguete-Torres M.D. Andrea Cercek Hear from four patients who participated in the clinical trial and how it changed their lives. #ASCO22 ASCO NEJM @AndreCercek

SU2Cscience Stand Up To Cancer Hear from four patients who participated in the clinical trial and how it changed their lives. #ASCO22 ASCO NEJM @AndreCercek

All smiles from the Andrea Cercek research team after her ground-breaking presentation. “This has never happened in the history of cancer” from The New York Times nytimes.com/2022/06/05/hea…

Now published in NEJM we describe 100% clinical CR with dostarlimab alone in 12 patients with locally advanced dMMR rectal cancer!Our team leader Andrea Cercek Memorial Sloan Kettering Cancer Center presenting the data ASCO #ASCO22

Unbelievable data presented by Andrea Cercek with 100% CR for MSI rectal cancer with dostarlimab. No surgery, no chemo, no radiation and NO CANCER! Congrats you all! Andrea Cercek Melissa Lumish MD, Luiz Diaz and Memorial Sloan Kettering Cancer Center team! OncoAlert #asco22

'A complete remission in every single patient is “unheard-of”' Combining genomics diagnosis of mismatch repair deficient + PD-1 immunotherapy led to complete remission of 18 consecutive patients w/ advanced colorectal cancer nejm.org/doi/full/10.10… nytimes.com/2022/06/05/hea… #ASCO22

With the right molecular signal, a cancer drug works in every patient statnews.com/2022/06/05/wit… via STAT Andrea Cercek #ASCO22

Impressive work, congratulations to Dr. Andrea Cercek and her team! Memorial Sloan Kettering Cancer Center this is Practice Changing 👏🏻👏🏻 #ASCO2022 OncoAlert

Very proud of our study published in NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! ASCO #ASCO22 Memorial Sloan Kettering Cancer Center nejm.org/doi/full/10.10…

via ⁦The New York Times Small trial, Big Results nytimes.com/2022/06/05/hea…

Exciting results out of #ASCO22: The Memorial Sloan Kettering Cancer Center doctors decided to change the study so that patients would not require radiation, chemotherapy, or surgery. Just six months of immunotherapy treatment was enough by itself. statnews.com/2022/06/05/wit… via STAT

Dr Luis Diaz of Memorial Sloan Kettering Cancer Center discusses the challenges of how MSS tumors don't respond to ✅ point inhibitors, low TMB and low PDL1 and peritumoral inflammation #crcsm #GIonc #ASCO22

A recent Memorial Sloan Kettering Cancer Center trial had an unprecedented success rate — and it could have dramatic implications for other cancers: “The tumor’s completely gone.”

Check out our new publication with Memorial Sloan Kettering Cancer Center demonstrating #ecDNA - based KRAS G12C amplification as a recurrent resistance mechanism to KRASG12Ci + EGFRi treatment in CRC! aacrjournals.org/cancerdiscover… KRAS Kickers #oncology